Filing Details
- Accession Number:
- 0001209191-22-001202
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-01-04 21:00:09
- Reporting Period:
- 2021-12-30
- Accepted Time:
- 2022-01-04 21:00:09
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1655759 | Arvinas Inc. | ARVN | Pharmaceutical Preparations (2834) | 472566120 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1783868 | Ronald Peck | C/O Arvinas, Inc. 5 Science Park, 395 Winchester Avenue New Haven CT 06511 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-12-30 | 14,375 | $47.38 | 19,777 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2021-12-30 | 5,625 | $26.58 | 25,402 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-12-30 | 11,371 | $80.35 | 14,031 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-12-30 | 8,629 | $80.96 | 5,402 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2021-12-30 | 14,375 | $0.00 | 14,375 | $47.38 |
| Common Stock | Stock Option (right to buy) | Disposition | 2021-12-30 | 5,625 | $0.00 | 5,625 | $26.58 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 40,625 | 2030-02-26 | No | 4 | M | Direct | |
| 46,559 | 2029-07-28 | No | 4 | M | Direct |
Footnotes
- The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020.
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 31, 2020.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.76 to $80.755, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.76 to $81.515, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range set forth in this footnote.
- This option award was granted on February 27, 2020. 1/4 of the shares underlying the award vested on February 27, 2021, with the remainder of the shares vesting in equal monthly installments following February 27, 2021 through February 27, 2024.
- This option award was granted on July 29, 2019. 1/4 of the shares underlying the award vested on July 29, 2020, with the remainder of the shares vesting in equal monthly installments following July 29, 2020 through July 29, 2023.
Billionaire Hedge Funds
